Acknowledgment: Funding for this study was provided by sanofi-aventis, U.S.
1. Carlson RW, Allred DC, Anderson BO, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, V.1.2009. http://www. nccn.org. Accessed May 12, 2011.
2. Gadjos C, Tartter PI, Estabrook A, et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002;80:4–11.
3. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathologic response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125–131.
4. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999;17:441–444.
5. Schneeweiss A, Bastert G, Huober J, et al. Neoadjuvant therapy with gemcitabine in breast cancer. Oncology 2004;18:27–31.
6. Gradishar WJ, Wedam SB, Jahanzeb M, et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005;8:1297–1304.
7. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathologic response and breast conservation rate. Br J Cancer 2003;88:1339–1345.
8. Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biologic markers in a phase II, multicenter study. Clin Cancer Res 2003;9:686–692.
9. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol 2006;24:2019–2027.
10. Hamm JT, Wilson JW, Rastogi P, et al. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2008;8:257–263
11. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony- stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 2007;20:2012–2018.
12. Sarid D, Ron IG, Sperber F et al. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study. Clin Drug Investig 2006;26:691–701.
13. Thatai LC, Vishnubhotla P, Biernat L, et al. A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer. Am J Clin Oncol 2006;29:484–489.
14. Aguiar-Bujanda D, Bohn-Sarmiento U, Cabrera-Suarez MA, et al. Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer. J Cancer Res Clin Oncol 2006;132:332–338.
15. Cooper BW, Radivovevitch T, Overmoyer BA, et al. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 2006;97:311–318.
16. Ramaswamy B, Povoski SP, Rhoades C, et al. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 2005;93:67–74.
17. Reitsamer R, Peintinger F, Prokop E, et al. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005;16:867–870.
18. O’Regan RM, Von Roenn JH, Carlson RW, et al. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/ cyclophosphamide) in stage III breast cancer. Clin Breast Cancer 2005;6:163–168.
19. Chua S, Smith IE, A’Hern RP, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard Adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomized phase III trial (TOPIC 2). Ann Oncol 2005;16:1435–1441.
20. Chen SC, Chang HK, Lin YC, et al. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. Onkologie 2005;28:339–344.
21. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988–2995.
22. Abrial C, Van Praagh I, Delva R, et al. Pathologic and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist 2005;10:242–249.
23. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958– 4965.
24. Mouret-Reynier MA, Abrial CJ, Ferriere JP, et al. Neoadjuvant FEC100 for operable breast cancer: eight year experience of Centre Jean Perrin. Clin Breast Cancer 2004;5:303–307.
25. Espinosa E, Morales S, Borrega P, et al. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol 2004;54:546–552.
26. Smith IE, A’Hern RP, Coombes GA, et al. A novel continuous infusional 5-fluorouracil- based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15:751–758.
27. Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004;90:968–974.
28. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676–2685.
29. Gogas H, Papadimitriou C, Kalofonos HP, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002;13:1737–1742. 30. Braud AC, Levy E, Feuilhade F, et al. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: a phase II study. Am J Clin Oncol 2002;25:303–307. 31. de Matteis A, Nuzzo F, D’Aiuto G, et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 2002;94:895–901. 32. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002(suppl 3):S69–S74. 33. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685. 34. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013–1019.
35. Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5´deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999;83:127–134.
36. Yamamoto S, Kurebayashi J, Kurosumi M, et al. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. Cancer Chemother Pharmacol 2001;48:283–288.
37. Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 2004;10:6764–6769.
38. Lee KS, Ro J, Nam BH, et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 2008;109:481–489.
39. Hurley J, Reis I, Silva O, et al. Weekly docetaxel/carboplatin as primary systemic therapy for Her2-negative locally advanced breast cancer. Clin Breast Cancer 2005;6:447–454.
40. Lee YJ, Doliny P, Gomez-Fernandez C, et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 2004;5:371–376.
41. Morrell LE, Lee YJ, Hurley J, et al. A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 1998;82:503–511.
42. Villman K, Ohd JF, Lidbrink E, et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007;43:1153–1160.
43. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009;27(15S):502.
44. Garber J, Richardson A, Harris L, et al. Neoadjuvant cisplatin in “triple-negative” breast cancer. Presented at the 29th San Antonio Breast Cancer Symposium; December 14– 17, 2006; San Antonio, TX. Poster 3074.
45. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 2007;19:2650–2655.
46. Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.0. National Cancer Institute, 1999. http://ctep.cancer. gov. Accessed May 12, 2011.
47. Layman RM, Thomas DG, Griffith KA, et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 2007;13:4092–4097.
48. Le Tourneau C, Dettwiler S, Beuzeboc P, et al. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. Am J Clin Oncol 2011. doi: 10.1097/ COC.0b013e318209d34c (Epub ahead of print).
49. Blakely L, Somer B, Keaton M, et al. Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for Her2+ operable breast cancer. J Clin Oncol 2009;27(15S):595.
50. Gianni L, Semiglazov V, Manikhas GM, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumour and safety analysis. J Clin Oncol 2007;25(18S):532.
51. Leone JP, Guardiola V, Venkatraman A, et al. Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): retrospective analysis of 125 patients. J Clin Oncol 2009;27(15S):625.
52. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracyclinetaxane- based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133–140.
53. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–5116.
54. Mamounas EP. Facilitating breastconserving surgery and preventing recurrence: aromatase inhibitors in the neoadjuvant and adjuvant settings. Ann Surg Oncol 2008;15:691–703.
55. American College of Surgeons, National Cancer Institute, and Cancer and Leukemia Group B. Exemestane, letrozole, or anastrozole in treating postmenopausal women who are undergoing surgery for stage II or stage III breast cancer. ClinicalTrials.gov NCT00265759. http://clinicaltrials.gov. Accessed May 12, 2011.
56. Keam B, Im SA, Lee KH, et al. Ki67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011 March 2;13(2):R22 (Epub ahead of print).